Diabetes & metabolic syndrome
-
Diabetes Metab Syndr · Jul 2020
COVID-19 outbreak in Iraqi Kurdistan: The first report characterizing epidemiological, clinical, laboratory, and radiological findings of the disease.
On March 11, 2020, the novel coronavirus was declared a global pandemic. The disease was named COVID-19 standing for coronavirus disease 2019. The objectives were to determine the epidemiological, clinical, laboratory, and radiological characteristics of COVID-19 patients. ⋯ All COVID-19 cases were linked to foreign visits with few local transmissions to close contacts without community transmission. The majority of cases were mild illnesses with full recovery.
-
Diabetes Metab Syndr · Jul 2020
ReviewTelemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians.
In view of restrictions on mobility of patients because of COVID-19 pandemic, face-to-face consultations are difficult. We sought to study the feasibility of telemedicine in this scenario. ⋯ Telemedicine is a useful tool for managing patients of diabetes during this lockdown period. However, there is limited data and further research is required.
-
Diabetes Metab Syndr · Jul 2020
ReviewSARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects.
According to the World Obesity Federation, "obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)"; additionally the Centres for Disease Control and Prevention reported that "people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness". Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection. ⋯ Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese.
-
Diabetes Metab Syndr · Jul 2020
ReviewRemdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. ⋯ Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.
-
Diabetes Metab Syndr · Jul 2020
ReviewSARS-CoV-2 infection and glucose homeostasis in pregnancy. What about antenatal corticosteroids?
Administration of corticosteroids is common in obstetric practice. In this concise review we queried on the effects of corticosteroids in pregnancies complicated by SARS-CoV-2. ⋯ Caution should be exercised while using corticosteroids in pregnant women with COVID-19 requiring preterm delivery.